These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 34674181)

  • 1. Emerging Concepts of Endotypes/Phenotypes in Regenerative Medicine for Osteoarthritis.
    Im GI; Moon JY
    Tissue Eng Regen Med; 2022 Apr; 19(2):321-324. PubMed ID: 34674181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Development of Disease-Modifying Therapies for Osteoarthritis (DMOADs): The Evidence to Date.
    Oo WM; Little C; Duong V; Hunter DJ
    Drug Des Devel Ther; 2021; 15():2921-2945. PubMed ID: 34262259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Concept of Early Osteoarthritis and Its Significance in Regenerative Medicine.
    Im GI
    Tissue Eng Regen Med; 2022 Jun; 19(3):431-436. PubMed ID: 35244885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The current state of the osteoarthritis drug development pipeline: a comprehensive narrative review of the present challenges and future opportunities.
    Kim H; Seo J; Lee Y; Park K; Perry TA; Arden NK; Mobasheri A; Choi H
    Ther Adv Musculoskelet Dis; 2022; 14():1759720X221085952. PubMed ID: 36504595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Models for Development of Disease-Modifying Osteoarthritis Drugs.
    Makarczyk MJ; Gao Q; He Y; Li Z; Gold MS; Hochberg MC; Bunnell BA; Tuan RS; Goodman SB; Lin H
    Tissue Eng Part C Methods; 2021 Feb; 27(2):124-138. PubMed ID: 33403944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular taxonomy of osteoarthritis for patient stratification, disease management and drug development: biochemical markers associated with emerging clinical phenotypes and molecular endotypes.
    Mobasheri A; van Spil WE; Budd E; Uzieliene I; Bernotiene E; Bay-Jensen AC; Larkin J; Levesque MC; Gualillo O; Henrotin Y
    Curr Opin Rheumatol; 2019 Jan; 31(1):80-89. PubMed ID: 30461544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoarthritis phenotypes and novel therapeutic targets.
    Van Spil WE; Kubassova O; Boesen M; Bay-Jensen AC; Mobasheri A
    Biochem Pharmacol; 2019 Jul; 165():41-48. PubMed ID: 30831073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects of Disease-Modifying Osteoarthritis Drugs.
    Oo WM
    Clin Geriatr Med; 2022 May; 38(2):397-432. PubMed ID: 35410687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis.
    Abadie E; Ethgen D; Avouac B; Bouvenot G; Branco J; Bruyere O; Calvo G; Devogelaer JP; Dreiser RL; Herrero-Beaumont G; Kahan A; Kreutz G; Laslop A; Lemmel EM; Nuki G; Van De Putte L; Vanhaelst L; Reginster JY;
    Osteoarthritis Cartilage; 2004 Apr; 12(4):263-8. PubMed ID: 15023377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanomedicine and regenerative medicine approaches in osteoarthritis therapy.
    Goudarzi R; Dehpour AR; Partoazar A
    Aging Clin Exp Res; 2022 Oct; 34(10):2305-2315. PubMed ID: 35867240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of inflammation on the osteoarthritic niche: implications for regenerative medicine.
    Williams EL; Edwards CJ; Cooper C; Oreffo RO
    Regen Med; 2012 Jul; 7(4):551-70. PubMed ID: 22817628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in understanding the phenotypes of osteoarthritis.
    Mobasheri A; Saarakkala S; Finnilä M; Karsdal MA; Bay-Jensen AC; van Spil WE
    F1000Res; 2019; 8():. PubMed ID: 31885861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An update on the pathophysiology of osteoarthritis.
    Mobasheri A; Batt M
    Ann Phys Rehabil Med; 2016 Dec; 59(5-6):333-339. PubMed ID: 27546496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Trends in Pharmacological Treatments for Osteoarthritis.
    Cai X; Yuan S; Zeng Y; Wang C; Yu N; Ding C
    Front Pharmacol; 2021; 12():645842. PubMed ID: 33935742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotypes and endotypes of rhinitis and their impact on management: a PRACTALL report.
    Papadopoulos NG; Bernstein JA; Demoly P; Dykewicz M; Fokkens W; Hellings PW; Peters AT; Rondon C; Togias A; Cox LS
    Allergy; 2015 May; 70(5):474-94. PubMed ID: 25620381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The future of deep phenotyping in osteoarthritis: How can high throughput omics technologies advance our understanding of the cellular and molecular taxonomy of the disease?
    Mobasheri A; Kapoor M; Ali SA; Lang A; Madry H
    Osteoarthr Cartil Open; 2021 Dec; 3(4):100144. PubMed ID: 36474763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repurposed and investigational disease-modifying drugs in osteoarthritis (DMOADs).
    Oo WM; Hunter DJ
    Ther Adv Musculoskelet Dis; 2022; 14():1759720X221090297. PubMed ID: 35619876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OA clinical trials: current targets and trials for OA. Choosing molecular targets: what have we learned and where we are headed?
    Hellio Le Graverand-Gastineau MP
    Osteoarthritis Cartilage; 2009 Nov; 17(11):1393-401. PubMed ID: 19426849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoarthritis, part of life or a curable disease? A bird's-eye view.
    Englund M
    J Intern Med; 2023 Jun; 293(6):681-693. PubMed ID: 37004213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanotechnological Strategies for Osteoarthritis Diagnosis, Monitoring, Clinical Management, and Regenerative Medicine: Recent Advances and Future Opportunities.
    Mohammadinejad R; Ashrafizadeh M; Pardakhty A; Uzieliene I; Denkovskij J; Bernotiene E; Janssen L; Lorite GS; Saarakkala S; Mobasheri A
    Curr Rheumatol Rep; 2020 Apr; 22(4):12. PubMed ID: 32248371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.